
In his debut blog, Kris Deering summarises a paper which looks at the evidence gaps and research priorities for early intervention in psychosis.
[read the full story...]In his debut blog, Kris Deering summarises a paper which looks at the evidence gaps and research priorities for early intervention in psychosis.
[read the full story...]In her debut blog, Natalie Kashirsky explores a qualitative study finding valuable mechanisms of peer support in early intervention in psychosis services.
[read the full story...]In her debut blog, Natasha Chilman blogs about a Swedish cohort study of 1.3 million people, which finds that migrants with first episode psychosis are more likely to receive inpatient care.
[read the full story...]Dave Steele explores a systematic review which finds that people who are at risk of psychosis are likely to experience stigma and discrimination.
[read the full story...]In her debut blog, Rosa Pitts summarises the ARIES trial, which suggests it may be feasible to use a smartphone app (My Journey 3) to help prevent relapse in psychosis, although questions remain about long-term participant engagement with the app.
[read the full story...]Joe Pierre summarises two recently published and widely reported RCTs, which suggest that antipsychotic medication might not offer an advantage over psychotherapy in broadly-defined first episode psychosis.
[read the full story...]Danny Whiting explores the issue of screening for first episode psychosis in prison using a retrospective cohort study from Australia.
[read the full story...]Carla McEnery summarises a systematic review and meta-analysis of interventions and social functioning in youth at risk of psychosis.
[read the full story...]Elwira Lubos summarises a recent review of reviews looking at the evidence for improving outcomes in first-episode psychosis.
[read the full story...]Lisa Wood publishes her debut blog about a recent RCT of social recovery therapy in combination with early intervention services for enhancement of social recovery in patients with first-episode psychosis: the SUPEREDEN3 trial.
[read the full story...]